Recursion Therapeutics reported delivery of a whole‑genome microglia ‘phenomap’ built from 46 million microglial cell images and perturbation data to Roche and Genentech under their collaboration, triggering a $30 million milestone payment. The map is designed to identify novel microglial targets across neuroscience indications including Alzheimer’s and Parkinson’s diseases. The phenomap is the second neuroscience map optioned in the partnership and brings Recursion’s total cash receipts from Roche/Genentech to about $213 million to date. The collaboration uses Recursion’s Recursion OS and phenotypic screening to accelerate target discovery across dozens of programs. Roche and Genentech have rights to use the phenomap within a broader up‑to‑$12 billion collaboration; the milestone underscores the commercial viability of large‑scale, image‑driven phenomics as a discovery engine for complex neurodegenerative biology.